QNCX, US22053A1079

IRulya schedules October 22 conference: what it means for IRulya Therapeutics stock

Published on 10/21/2026 at 05:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IRulya posted October 19 data showing 81.30 m in six patients. IRulya Therapeutics stock now centers on 3 Phase 2 programs and USD 116 million cash.

Clinical milestones move forward

IRulya reported a 24-week 81.30-meter walk-distance gain on October 19, 2026.
The October 9, 2026 relaunch included USD 115 million in upfront financing.
Craig-Hallum conference participation is scheduled for October 22, 2026.

QNCX, US22053A1079, Illustration mit AI erstellt.

IRulya Therapeutics Inc. (ISIN US22053A1079) reported a 24-week mean improvement of 81.30 meters in six evaluable patients in a Phase 2a LAM-001 analysis, according to StockTitan on October 19, 2026. The filing places the result beside a 67.40-meter gain in the pulmonary hypertension subgroup, while the study remains open-label and small.

October presentation adds clinical detail

The October 19, 2026 presentation described LAM-001 as a once-daily inhaled rapamycin candidate across three Phase 2 programs. Exercise pulmonary vascular resistance declined 25.50 percent in the evaluable population and 35.30 percent in the subgroup, according to StockTitan. The same filing said five of 19 subjects had an FEV1 decline greater than 10 percent in a February 2026 interim review, but the blinded study remains ongoing.

What does the pipeline mean?

The development plan links the October 19 update to three milestones: bronchiolitis obliterans syndrome data in the first quarter of 2027, pulmonary hypertension associated with interstitial lung disease data in the first quarter of 2028, and sarcoidosis-associated pulmonary hypertension data in the fourth quarter of 2028. The company also anticipates starting the SAPH study in the fourth quarter of 2026, according to StockTitan.

Three milestones reshape the story

On October 6, 2026, stockholders approved transactions expected to leave 10,841,470 common shares outstanding. On October 9, 2026, the company relaunched as IRulya, announced USD 115 million in upfront financing and said cash stood at USD 116 million on June 30, 2026. On October 19, 2026, it posted the updated clinical presentation, according to IRulya Therapeutics.

Two dates define the next steps

IRulya is scheduled to participate in the Craig-Hallum Biotech Catalyst Conference on October 22, 2026, according to IRulya Therapeutics. The next major clinical date is the expected BOS data readout in the first quarter of 2027.

Clinical evidence remains the key test

The 81.30-meter result gives the October presentation a measurable signal, but the evaluable group contains six patients and the BOS interim review remains blinded. For investors, the next milestones combine a near-term conference appearance with data expected from larger Phase 2 programs.